ArticleFuture oncology (London, England)2025
A Phase 1 study of the novel GCN2 kinase activator NXP800 in patients with advanced cholangiocarcinoma.
Hendrien Kuipers et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it